Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002760 · ClinicalTrials.gov registry record · Phase 3
Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 260
- Enrollment target
NCT00002760 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 260 participants.
The verdict
NCT00002760, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 260 participants
- Enrollment target
Study Summary
RATIONALE: Antiandrogen withdrawal may be an effective treatment for prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of ketoconazole and hydrocortisone for antiandrogen withdrawal in treating men with prostate cancer that is refractory to hormone therapy.
Interventions
- DRUG ketoconazole
- DRUG therapeutic hydrocortisone
- OTHER Withdrawal of antiandrogen therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 1996-08 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002760
The ClinicalTrials.gov registry entry for NCT00002760 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ketoconazole is the first listed.
NCT00002760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002760 about?
NCT00002760 is a clinical study titled "Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer". RATIONALE: Antiandrogen withdrawal may be an effective treatment for prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of ketoconazole and hydrocortisone for antiandrogen withdrawal in treating men with prostate cancer that is refractory to hormone therapy.
What is the current status of trial NCT00002760?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 260 participants. The study started on 1996-08. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00002760?
The interventions under investigation include: ketoconazole (DRUG), therapeutic hydrocortisone (DRUG), Withdrawal of antiandrogen therapy (OTHER).
Who is sponsoring clinical trial NCT00002760?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.